Bilcare Research has introduced a new high-speed lamination line for the production of Aclar multilayer films and Triplex PVdC Films at its Bötzingen facility in Germany. This investment, along with the expansion of PVdC coating capacities at its Singapore facility, provides added capabilities to meet increasing demands in the North American market. These investments provide additional manufacturing capacity for Aclar lamination and PVdC coating capabilities with multiple global locations to support North American customers in a more cost-efficient position from its U.S. facility.
 
According to the company, its range of Aclar laminates provides the highest moisture barrier of any films of their kind, and the films are crystal clear, biochemically inert, chemical-resistant, non-flammable and free of plasticizers and stabilizers, according to the company. Bilcare Research also is introducing Aclar laminates with features that create unique identities to pharma brands.  
 
“This investment in our new laminating line is the latest component of our continued growth strategy to meet the needs of rapidly-evolving business models in the global pharmaceutical industry,” said Thorsten Kühn, chief executive officer of Bilcare Research AG, Switzerland. “We see increased demand across our entire range of Bilcare Aclar laminates, from both innovator and generic pharmaceutical companies.”